BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, July 27, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» China's NMPA clears IND for anti-CCR8 monoclonal antibody CM-369
To read the full story,
subscribe
or
sign in
.
China's NMPA clears IND for anti-CCR8 monoclonal antibody CM-369
Aug. 24, 2022
No Comments
China's National Medical Products Administration (NMPA) has cleared an IND for CM-369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by Tiannuojiancheng Pharma, a joint venture between InnoCare Pharma and Keymed Biosciences.
BioWorld Science
Immuno-oncology